Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
May 1, 2023
February 7, 2024
a1bfde05-8672-4537-9ef7-bdf6377a9f3b
Related Documents
Assessing User Fees Under the Biosimilar User Fee Amendments of 2022: Guidance for Industry
Guidance DocumentJuly 31, 2023Center for Drug Evaluation and Research
Benefit-Risk Assessment for New Drug and Biological Products
Guidance DocumentOctober 17, 2023Center for Drug Evaluation and Research
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry: Guidance for Industry
Guidance DocumentNovember 9, 2020Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox